(EKTA-B) Elekta (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000163628
EKTA-B: Radiation Therapy, Radiosurgery, Brachytherapy, Neurosurgery
Elekta AB (publ), a global leader in medical technology, specializes in developing clinical solutions for cancer and brain disorder treatments. The company offers a comprehensive portfolio of radiation therapy products, including Elekta Unity, the worlds first high-field MR-guided linear accelerator; Elekta Versa HD, designed for advanced brain metastases treatment; and Elekta Infinity, a versatile system addressing diverse radiotherapy needs. Its product lineup also features Elekta Harmony, a high-precision linear accelerator, and Elekta Esprit, a stereotactic radiosurgery system. The company further provides Leksell Gamma Knife Icon and Perfexion, which are industry benchmarks for personalized radiation therapy and radiosurgery. Elektas software solutions include Elekta ONE, a unified platform integrating multiple clinical applications, and Leksell GammaPlan, a treatment planning software for radiosurgery. In brachytherapy, Elekta offers Elekta Studio, Oncentra Brachy, and Elekta Xoft Axxent, along with applicators like Elekta Geneva and Venezia for cervical cancer treatment. The company also provides veterinary radiation therapy solutions and neurosurgery products such as Leksell Vantage Stereotactic System. Established in 1972, Elekta is headquartered in Stockholm, Sweden, and operates globally with a strong focus on innovation in oncology and neurosurgery. Web URL: https://elekta.com
Elektas product range is complemented by quality assurance and motion management solutions, ensuring precise and safe treatment delivery. The companys commitment to advancing cancer care is reflected in its continuous R&D investments and collaborations with leading healthcare institutions. Elektas solutions are designed to enhance treatment outcomes, streamline workflows, and improve patient experiences. With a focus on personalized medicine, the company remains at the forefront of radiation therapy innovation, addressing the growing demand for advanced cancer treatment options worldwide.
Additional Sources for EKTA-B Stock
EKTA-B Stock Overview
| Market Cap in USD | 1,850m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
EKTA-B Stock Ratings
| Growth Rating | -52.1 |
| Fundamental | 45.1 |
| Dividend Rating | 61.9 |
| Rel. Strength | -30 |
| Analysts | - |
| Fair Price Momentum | 43.07 SEK |
| Fair Price DCF | 32.72 SEK |
EKTA-B Dividends
| Dividend Yield 12m | 4.22% |
| Yield on Cost 5y | 3.22% |
| Annual Growth 5y | 5.92% |
| Payout Consistency | 90.8% |
EKTA-B Growth Ratios
| Growth Correlation 3m | -93% |
| Growth Correlation 12m | -73.8% |
| Growth Correlation 5y | -63.8% |
| CAGR 5y | -7.65% |
| CAGR/Max DD 5y | -0.12 |
| Sharpe Ratio 12m | 0.09 |
| Alpha | -40.66 |
| Beta | 0.753 |
| Volatility | 30.81% |
| Current Volume | 567.7k |
| Average Volume 20d | 990.8k |
As of April 26, 2025, the stock is trading at SEK 49.90 with a total of 567,676 shares traded.
Over the past week, the price has changed by +3.36%, over one month by -10.73%, over three months by -22.00% and over the past year by -29.81%.
Partly, yes. Based on ValueRay Fundamental Analyses, Elekta (publ) (ST:EKTA-B) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 45.13 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EKTA-B as of April 2025 is 43.07. This means that EKTA-B is currently overvalued and has a potential downside of -13.69%.
Elekta (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, EKTA-B Elekta (publ) will be worth about 48.3 in April 2026. The stock is currently trading at 49.90. This means that the stock has a potential downside of -3.21%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 67.1 | 34.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 48.3 | -3.2% |